Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Articles / Oct / A Moonshot for COVID-19
Discovery & Development COVID-19 Drug Discovery Research News

A Moonshot for COVID-19

Meet the international coalition working to tackle COVID-19 in low- and middle-income countries

By Angus Stewart 10/02/2021 1 min read Quick Read (pre 2022)

Share

An open-science consortium fighting for accessible COVID-19 treatments has received £8 million from the Wellcome Trust, a London-based charitable foundation focused on health research. The group, COVID Moonshot, was born in the early days of global lockdown. At that time, an international cross-section of scientists, academics, pharmaceutical research teams, and students began a collaborative race to identify new molecules that could block SARS-CoV-2 infection and to develop pills ready to roll out to those most in need of affordable medicine.

Alpha Lee, of the University of Cambridge, noted that Moonshot’s early efforts – focused on repurposing existing small molecule drugs and rapidly developing monoclonal antibodies – have now shifted to developing new antiviral therapeutics in light of the likely persistence of COVID-19 as a global threat.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Angus Stewart

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.

More Articles by Angus Stewart

False

Advertisement

Recommended

False

Related Content

Mpox Emergency
COVID-19 Supply Chain Trends & Forecasts
Mpox Emergency

August 27, 2024

2 min read

The mpox Public Health Emergency of International Concern is inviting a coordinated response. How can the industry implement lessons learned from COVID-19 to help?

Regeneron on the Digital Age of Clinical Trials
Clinical Trials COVID-19 Technology and Equipment Trends & Forecasts
Regeneron on the Digital Age of Clinical Trials

June 4, 2024

6 min read

Since the pandemic, the world has taken more interest in clinical trials. How are clinical trials adapting? We asked Bari Kowal, Regeneron’s head of development operations and portfolio management.

Interviews To Inspire
Profession Technology and Equipment Trends & Forecasts Advanced Medicine Drug Delivery Drug Discovery COVID-19
Interviews To Inspire

January 2, 2024

1 min read

Thoughtful and inspiring video interviews and roundtables from the past year

The Shadow of COVID-19
Vaccines COVID-19 Supply Chain Contract Manufacturing Services
The Shadow of COVID-19

November 28, 2023

10 min read

The effects of the biggest healthcare crisis in modern memory continues to linger, but lessons have been learned. In Europe, the European Commission has already struck deals to ensure manufacturing capacity for future emergencies.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.